Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results

1. Amgen, a leading biotechnology company, has decided to discontinue its obesity drug development program following the results of Phase 1 clinical trials.
2. The decision to halt the obesity program was based on the evaluation of the risk-benefit profile and commercial potential of the asset.
3. Amgen will now shift its focus to MariTide, a promising drug candidate in its pipeline, which has shown potential in preclinical studies.
4. MariTide is being developed for an undisclosed indication, and Amgen plans to initiate clinical trials for this drug candidate in the near future.
5. The move highlights Amgen's strategic approach to drug development, prioritizing assets with the highest potential for clinical and commercial success.
6. Amgen's decision to axe the obesity asset underscores the challenges and risks involved in developing new drugs, particularly in competitive therapeutic areas like obesity.
7. The company's focus on MariTide reflects its commitment to addressing unmet medical needs and delivering innovative therapies to patients.